RU2314316C2 - Антитела к человеческому мср-1 - Google Patents

Антитела к человеческому мср-1 Download PDF

Info

Publication number
RU2314316C2
RU2314316C2 RU2003100512/13A RU2003100512A RU2314316C2 RU 2314316 C2 RU2314316 C2 RU 2314316C2 RU 2003100512/13 A RU2003100512/13 A RU 2003100512/13A RU 2003100512 A RU2003100512 A RU 2003100512A RU 2314316 C2 RU2314316 C2 RU 2314316C2
Authority
RU
Russia
Prior art keywords
mcp
amino acid
binding
antibody
cdr2
Prior art date
Application number
RU2003100512/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2003100512A (ru
Inventor
Петер ХИШТАНД (CH)
Петер ХИШТАНД
Ханс ХОФШТЕТТЕР (CH)
Ханс ХОФШТЕТТЕР
Тревор Глин ПЕЙН (CH)
Тревор Глин Пейн
Роман УРФЕР (CH)
Роман УРФЕР
Франко Э. ДИ-ПАДОВА (CH)
Франко Э. ДИ-ПАДОВА
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2003100512A publication Critical patent/RU2003100512A/ru
Application granted granted Critical
Publication of RU2314316C2 publication Critical patent/RU2314316C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2003100512/13A 2000-06-30 2001-06-29 Антитела к человеческому мср-1 RU2314316C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds
GB0016138.0 2000-06-30

Publications (2)

Publication Number Publication Date
RU2003100512A RU2003100512A (ru) 2004-07-10
RU2314316C2 true RU2314316C2 (ru) 2008-01-10

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003100512/13A RU2314316C2 (ru) 2000-06-30 2001-06-29 Антитела к человеческому мср-1

Country Status (27)

Country Link
US (1) US20040047860A1 (https=)
EP (1) EP1299421B1 (https=)
JP (2) JP3920215B2 (https=)
KR (1) KR100603899B1 (https=)
CN (1) CN100486996C (https=)
AR (1) AR046379A1 (https=)
AT (1) ATE426616T1 (https=)
AU (2) AU2001283903B2 (https=)
BR (1) BR0112086A (https=)
CA (1) CA2412775A1 (https=)
CZ (1) CZ20024256A3 (https=)
DE (1) DE60138102D1 (https=)
EC (1) ECSP024402A (https=)
ES (1) ES2322643T3 (https=)
GB (1) GB0016138D0 (https=)
HU (1) HUP0301477A3 (https=)
IL (1) IL153721A0 (https=)
MX (1) MXPA03000201A (https=)
NO (1) NO20026063L (https=)
NZ (1) NZ523195A (https=)
PE (1) PE20020125A1 (https=)
PL (1) PL207133B1 (https=)
PT (1) PT1299421E (https=)
RU (1) RU2314316C2 (https=)
SK (1) SK18122002A3 (https=)
WO (1) WO2002002640A2 (https=)
ZA (1) ZA200300199B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP1461300B1 (en) 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
CA2496419A1 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
KR20050042801A (ko) * 2002-09-12 2005-05-10 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 ｍｃｐ-1 항체 및 그의 항체 단편
CA2544924A1 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2007147026A2 (en) * 2006-06-15 2007-12-21 Centocor, Inc. Ccr2 antagonists for chronic organ transplantation rejection
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
KR20090074787A (ko) * 2006-10-05 2009-07-07 센토코 오르토 바이오테크 인코포레이티드 섬유증 치료용 ｃｃｒ2 길항제
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
AU2008269954A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
ES2533493T3 (es) 2008-08-20 2015-04-10 Probiodrug Ag Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
CN107073112A (zh) * 2014-08-15 2017-08-18 皮克萨尔比奥公司 用于在患有脊髓损伤的对象中抑制炎症的组合物及其使用方法
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2022007479A (es) * 2019-12-18 2022-06-29 Hoffmann La Roche Anticuerpos anti-ccl2 biespecificos.
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2102479C1 (ru) * 1990-09-07 1998-01-20 Унилевер Н.В. Химерное моноклональное антитело, взаимодействующее с человеческой плацентарной щелочной фосфатазой, вариабельная область тяжелой гамма-цепи химерного моноклонального антитела, вариабельная область легкой k-цепи химерного моноклонального антитела, фрагмент кднк, кодирующий вариабельную область тяжелой гамма-цепи химерного моноклонального антитела и фрагмент кднк, кодирующий вариабельную область легкой k-цепи химерного моноклонального антитела

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2102479C1 (ru) * 1990-09-07 1998-01-20 Унилевер Н.В. Химерное моноклональное антитело, взаимодействующее с человеческой плацентарной щелочной фосфатазой, вариабельная область тяжелой гамма-цепи химерного моноклонального антитела, вариабельная область легкой k-цепи химерного моноклонального антитела, фрагмент кднк, кодирующий вариабельную область тяжелой гамма-цепи химерного моноклонального антитела и фрагмент кднк, кодирующий вариабельную область легкой k-цепи химерного моноклонального антитела

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLESS N.M. et al. Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1 RANTES) in acute lung injury in rats. J. Immunol. 2000, 164(5), с.2650-2659. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета

Also Published As

Publication number Publication date
ES2322643T3 (es) 2009-06-24
AU8390301A (en) 2002-01-14
HUP0301477A3 (en) 2005-11-28
US20040047860A1 (en) 2004-03-11
PL359854A1 (en) 2004-09-06
KR100603899B1 (ko) 2006-07-25
WO2002002640A2 (en) 2002-01-10
AR046379A1 (es) 2005-12-07
EP1299421A2 (en) 2003-04-09
PT1299421E (pt) 2009-06-26
CN100486996C (zh) 2009-05-13
MXPA03000201A (es) 2003-05-27
WO2002002640A3 (en) 2002-05-16
CZ20024256A3 (cs) 2003-04-16
SK18122002A3 (sk) 2003-06-03
PE20020125A1 (es) 2002-03-12
IL153721A0 (en) 2003-07-06
GB0016138D0 (en) 2000-08-23
ATE426616T1 (de) 2009-04-15
JP2004502421A (ja) 2004-01-29
BR0112086A (pt) 2003-05-06
NO20026063D0 (no) 2002-12-17
HUP0301477A2 (hu) 2003-08-28
AU2001283903B2 (en) 2005-06-02
KR20030014272A (ko) 2003-02-15
NZ523195A (en) 2005-09-30
JP3920215B2 (ja) 2007-05-30
DE60138102D1 (de) 2009-05-07
CN1443199A (zh) 2003-09-17
CA2412775A1 (en) 2002-01-10
ZA200300199B (en) 2003-11-13
PL207133B1 (pl) 2010-11-30
NO20026063L (no) 2003-02-27
JP2007054079A (ja) 2007-03-08
EP1299421B1 (en) 2009-03-25
ECSP024402A (es) 2003-02-06

Similar Documents

Publication Publication Date Title
RU2314316C2 (ru) Антитела к человеческому мср-1
JP3978338B2 (ja) ヒトＩＬ−１βに対する抗体
RU2286351C2 (ru) Антитела к человеческому il-1бета
AU2001283903A1 (en) Antibodies to human MCP-1
RU2426741C2 (ru) Антагонистические антитела к il-17
CN103724430B (zh) 抗mif抗体
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
KR101605908B1 (ko) Ｃｄ154에 특이적으로 결합하는, 항체, 항체 유도체 및 항체 단편을 포함하는 결합 단백질, 및 그의 용도
CA3194457A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha
KR101576559B1 (ko) 종양 괴사인자―α 인간화 항체
RU2656160C2 (ru) Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
RU2855920C1 (ru) Канинизированные антитела против альфа-рецептора интерлейкина-31 собаки
EP4617287A1 (en) Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120630